Nuvation Bio Financial Ratios
NYSE: NUVBHealth CareBiotechnology: Pharmaceutical PreparationsUSD
5.00+0.05 (+1.01%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Nuvation Bio ratio analysis
Nuvation Bio earned a net margin of -325.3% in FY 2025, up from -7213.8% a year earlier. Return on equity reached -66.9%, meaning Nuvation Bio generated -0.67 dollars of profit for every dollar of shareholders' equity. Debt-to-equity stood at 0.17 versus 0.01 the year before, and the current ratio was 6.95.
Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Nuvation Bio financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Price / sales | 0.05 | 0.10 | — | — | — | — |
| Price / book | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 5.31 |
| Gross margin | — | 10.1% | — | — | — | — |
| Operating margin | -338.7% | -7,527.3% | — | — | — | — |
| Net margin | -325.3% | -7,213.8% | — | — | — | — |
| Free cash flow margin | -288.4% | -1,656.5% | — | — | — | — |
| Return on equity (ROE) | -66.9% | -122.5% | -12.5% | -15.9% | -11.6% | -19.4% |
| Return on assets (ROA) | -34.4% | -105.1% | -12.2% | -15.5% | -11.2% | -18.8% |
| Debt / equity | 0.17 | 0.01 | 0.00 | — | — | — |
| Current ratio | 6.95 | 9.04 | 44.11 | 50.70 | 45.62 | 33.69 |
| Revenue growth | 699.0% | — | — | — | — | — |